CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 93 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $16,000 | -33.3% | 1,666 | -35.5% | 0.00% | 0.0% |
| Q4 2019 | $24,000 | +14.3% | 2,584 | -26.2% | 0.00% | 0.0% |
| Q3 2019 | $21,000 | +110.0% | 3,500 | +335.3% | 0.00% | – |
| Q2 2019 | $10,000 | -9.1% | 804 | +13.1% | 0.00% | -100.0% |
| Q3 2018 | $11,000 | -62.1% | 711 | -58.0% | 0.00% | -50.0% |
| Q2 2018 | $29,000 | +190.0% | 1,694 | +142.0% | 0.00% | +100.0% |
| Q3 2017 | $10,000 | -41.2% | 700 | -30.0% | 0.00% | -50.0% |
| Q1 2017 | $17,000 | -76.7% | 1,000 | -85.9% | 0.00% | -77.8% |
| Q4 2016 | $73,000 | +128.1% | 7,100 | +121.9% | 0.01% | +200.0% |
| Q3 2016 | $32,000 | +14.3% | 3,200 | +28.0% | 0.00% | -25.0% |
| Q2 2016 | $28,000 | +27.3% | 2,500 | +56.2% | 0.00% | +33.3% |
| Q1 2016 | $22,000 | -60.0% | 1,600 | -44.8% | 0.00% | -66.7% |
| Q4 2015 | $55,000 | +189.5% | 2,900 | +107.1% | 0.01% | +200.0% |
| Q4 2014 | $19,000 | -51.3% | 1,400 | -54.8% | 0.00% | -40.0% |
| Q3 2014 | $39,000 | – | 3,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 968,198 | $9,634,000 | 3.29% |
| INGALLS & SNYDER LLC | 1,382,048 | $13,751,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 700,710 | $6,972,000 | 0.66% |
| Alambic Investment Management, L.P. | 17,900 | $178,000 | 0.45% |
| RA Capital Management | 1,858,474 | $18,492,000 | 0.36% |
| Perceptive Advisors | 2,150,641 | $21,398,000 | 0.35% |
| Eversept Partners, LP | 232,983 | $2,318,181 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 17,351 | $173,000 | 0.10% |
| Alyeska Investment Group, L.P. | 502,783 | $5,003,000 | 0.08% |
| KENNEDY CAPITAL MANAGEMENT LLC | 263,958 | $2,626,000 | 0.08% |